Search Medical Condition
Please enter condition
Please choose location

Farmington, Michigan Clinical Trials

A listing of Farmington, Michigan clinical trials actively recruiting patient volunteers.

RESULTS

Found (141) clinical trials

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

This is a prospective, observational, population-based cohort study in US cystic fibrosis patients participating in the Cystic Fibrosis Patient Registry in order to assess the incidence of and risk factors for fibrosing colonopathy. Cystic fibrosis (CF) patients participating in the registry from participating sites, as well as new CF patients ...

Phase N/A

0.0 miles

Learn More »

A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease

The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety ...

Phase

2.06 miles

Learn More »

Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone

A study to evaluate the effectiveness of Liposomal Amikacin for Inhalation (LAI) when added to multi-drug regimen in subjects with Nontuberculous Mycobacterial (NTM) lung infection caused by Mycobacterium Avium Complex (MAC).

Phase

2.06 miles

Learn More »

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

The purpose of this study is to determine an effective and safe clinical dose of a new gadolinium-based contrast agent (GBCA) P03277 injection for Central Nervous System (CNS) lesion detection and visualization by conventional steady-state CNS imaging. Therefore, Contrast to Noise Ratio (CNR), a well-known quantitative parameter directly related to ...

Phase

2.06 miles

Learn More »

A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is an open label, Phase 1, dose escalation and dose confirmation study of ZEN003694 in patients with mCRPC.

Phase

2.06 miles

Learn More »

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

This is an open label, non-randomized, Phase 1b, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.

Phase

2.06 miles

Learn More »

A Multicenter Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off"

Each patient will participate for up to 62 weeks, which includes a Screening Period, followed by a Baseline Visit and open-label treatment for 1 year with a safety Follow-up 4 weeks after the last treatment. - Screening Period: up to 6 weeks. - Open-Label Treatment Period: 52 weeks (1 year) ...

Phase

2.94 miles

Learn More »

A Study to Evaluate the Efficacy of RO7046015 in Participants With Early Parkinson's Disease

This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous RO7046015 versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of 2 parts: a 52-week, double-blind, ...

Phase

2.94 miles

Learn More »

A Phase 2 RCT Study of CX-8998 for Essential Tremor

This is a multicenter, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks (with the exception of subjects on primidone at baseline who will be allowed 6 weeks of screening to allow for safe discontinuation). Screening results from all patients meeting the eligibility requirements will ...

Phase

2.94 miles

Learn More »

Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy Surgery and/or Radiation Therapy

This is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily) in early stage node-positive HER2 negative breast cancer patients. Patients will be randomized 1:1 within stratum defined by: Hormone Receptor status (HR positive vs HR negative), body mass index (<30 vs ≥ 30 kg/m2) and stage ...

Phase

2.94 miles

Learn More »